Wedbush set a $11.00 target price on Sangamo Therapeutics (NASDAQ:SGMO) in a report issued on Monday morning, Stock Target Advisor reports. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.
Separately, ValuEngine cut W&T Offshore from a hold rating to a sell rating in a research note on Friday, April 26th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Sangamo Therapeutics currently has a consensus rating of Hold and an average target price of $13.33.
Shares of NASDAQ:SGMO remained flat at $$11.27 during midday trading on Monday. The company had a trading volume of 1,124,138 shares, compared to its average volume of 2,182,844. Sangamo Therapeutics has a 12-month low of $6.26 and a 12-month high of $19.25. The company has a quick ratio of 3.98, a current ratio of 3.98 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.30 billion, a PE ratio of -16.10 and a beta of 2.99. The stock has a fifty day moving average price of $9.95.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.14). The company had revenue of $8.07 million during the quarter, compared to analyst estimates of $27.21 million. Sangamo Therapeutics had a negative net margin of 113.03% and a negative return on equity of 24.67%. On average, equities research analysts anticipate that Sangamo Therapeutics will post -1.46 earnings per share for the current year.
In other Sangamo Therapeutics news, CFO Kathy Yi sold 5,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $10.00, for a total transaction of $50,000.00. Following the completion of the sale, the chief financial officer now owns 30,512 shares of the company’s stock, valued at $305,120. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.30% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Pearl River Capital LLC acquired a new stake in shares of Sangamo Therapeutics in the first quarter valued at $94,000. Oppenheimer Asset Management Inc. grew its stake in shares of Sangamo Therapeutics by 47.3% in the first quarter. Oppenheimer Asset Management Inc. now owns 13,032 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 4,184 shares in the last quarter. Amalgamated Bank acquired a new stake in shares of Sangamo Therapeutics in the fourth quarter valued at $172,000. Cambridge Investment Research Advisors Inc. grew its stake in shares of Sangamo Therapeutics by 52.1% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 16,296 shares of the biopharmaceutical company’s stock valued at $187,000 after buying an additional 5,580 shares in the last quarter. Finally, Legal & General Group Plc grew its stake in shares of Sangamo Therapeutics by 9.3% in the fourth quarter. Legal & General Group Plc now owns 18,066 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 1,534 shares in the last quarter. 57.18% of the stock is owned by institutional investors and hedge funds.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Featured Story: What is the downside to momentum investing?
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.